Replimune Group Target of Unusually High Options Trading (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) was the recipient of some unusual options trading activity on Tuesday. Stock traders acquired 11,386 call options on the stock. This is an increase of 653% compared to the average volume of 1,513 call options.

Insider Transactions at Replimune Group

In other news, insider Christopher Sarchi sold 3,749 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $30,179.45. Following the completion of the sale, the insider owned 128,296 shares of the company's stock, valued at approximately $1,032,782.80. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Andrew Schwendenman sold 3,287 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $26,460.35. Following the completion of the transaction, the chief accounting officer directly owned 68,284 shares of the company's stock, valued at $549,686.20. This represents a 4.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 74,907 shares of company stock worth $603,655. 8.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Sterling Capital Management LLC raised its stake in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after purchasing an additional 1,655 shares during the last quarter. Graham Capital Management L.P. lifted its holdings in Replimune Group by 6.1% during the fourth quarter. Graham Capital Management L.P. now owns 30,180 shares of the company's stock worth $365,000 after acquiring an additional 1,731 shares during the period. Deutsche Bank AG boosted its holdings in shares of Replimune Group by 0.4% in the 1st quarter. Deutsche Bank AG now owns 563,701 shares of the company's stock worth $5,496,000 after buying an additional 2,140 shares during the last quarter. MetLife Investment Management LLC lifted its stake in Replimune Group by 7.2% in the fourth quarter. MetLife Investment Management LLC now owns 37,659 shares of the company's stock valued at $456,000 after purchasing an additional 2,525 shares during the last quarter. Finally, Arizona State Retirement System grew its stake in shares of Replimune Group by 19.7% during the 1st quarter. Arizona State Retirement System now owns 15,439 shares of the company's stock worth $151,000 after acquiring an additional 2,545 shares during the period. 92.53% of the stock is owned by institutional investors.

Replimune Group Trading Up 3.8%

Shares of REPL stock traded up $0.43 during mid-day trading on Tuesday, hitting $11.71. The company's stock had a trading volume of 1,376,144 shares, compared to its average volume of 902,373. The company has a market cap of $903.03 million, a PE ratio of -3.82 and a beta of 0.61. Replimune Group has a 52 week low of $6.44 and a 52 week high of $17.00. The company's fifty day simple moving average is $9.11 and its 200-day simple moving average is $10.47. The company has a debt-to-equity ratio of 0.17, a quick ratio of 7.95 and a current ratio of 7.95.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period last year, the business earned ($0.25) earnings per share. As a group, equities research analysts expect that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. HC Wainwright reissued a "buy" rating and set a $22.00 price target on shares of Replimune Group in a research note on Thursday, July 3rd. Piper Sandler lifted their target price on shares of Replimune Group from $14.00 to $22.00 and gave the stock an "overweight" rating in a research report on Monday, June 2nd. Finally, Cantor Fitzgerald began coverage on shares of Replimune Group in a report on Friday, June 20th. They set an "overweight" rating on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Replimune Group presently has an average rating of "Buy" and an average target price of $20.83.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.